Antigen |
Timing |
Men+Tdap+HPV |
Placebo+Tdap+HPV |
Vaccine Group Differences / Ratiosǂ |
|
|
n |
% of subjects/GMC |
n |
% of subjects/GMC |
|
|
|
|
% ≥1.0 IU/mL (95% CI) |
|
% ≥1.0 IU/mL (95% CI) |
Men+Tdap+HPV minus Placebo+Tdap+HPV (95% CI) |
Diphtheria |
|
|
|
|
|
|
|
Baseline |
375 |
5 (3, 8) |
380 |
3 (2, 5) |
2 (-1, 5) |
|
Month 1 |
376 |
95 (93, 97) |
382 |
82 (78, 86) |
13 (9, 17) |
Tetanus |
|
|
|
|
|
|
|
Baseline |
375 |
28 (24, 33) |
380 |
28 (23, 32) |
1 (-6, 7) |
|
Month 1 |
376 |
99 (97, 100) |
382 |
98 (97, 99) |
0 (-2, 2) |
Pertussis antigen |
|
|
GMC (IU/ml#) (95% CI) |
|
GMC (95% CI) |
Ratio of Men+Tdap+HPV to Placebo+Tdap+HPV (95% CI) |
PT |
Baseline |
375 |
4.77 (4.11, 5.53) |
380 |
4.16 (3.59, 4.82) |
1.15 (0.95, 1.39) |
Month 1 |
376 |
44 (40, 48) |
382 |
44 (40, 48) |
1.01 (0.89, 1.14) |
FHA |
Baseline |
375 |
24 (21, 27) |
380 |
21 (18, 23) |
1.15 (0.98, 1.34) |
Month 1 |
376 |
202 (187, 218) |
382 |
240 (222, 259) |
0.84 (0.76, 0.93) |
Pertactin |
Baseline |
375 |
20 (18, 23) |
380 |
21 (18, 24) |
0.99 (0.83, 1.18) |
Month 1 |
376 |
330 (300, 363) |
382 |
403 (367, 443) |
0.82 (0.72, 0.93) |
|